In this video, Motley Fool health-care bureau chief Brenton Flynn takes a closer look at Dendreon (NASDAQ: DNDN), a company that has underperformed recently, to shareholders' chagrin. Brenton looked at the company's recent SEC filings and gives us a few interesting pieces of information about the company he gleaned from them. For one thing, the company had been sitting on some zero-cost antigen inventory, and benefiting from that wasn't being recognized as an expense. Second, the company made a sharp move by selling its royalty rights to Merck's (NYSE: MRK) hepatitis C drug Victrelis last year for $125 million.
Motley Fool Returns
Discounted offers are only available to new members. Stock Advisor will renew at the then current list price. Stock Advisor list price is $199 per year.
Stock Advisor launched in February of 2002. Returns as of 10/25/2021.
Average returns of all recommendations since inception. Cost basis and return based on previous market day close.